Drug Profile
Veltuzumab - Immunomedics
Alternative Names: Anti-CD20 monoclonal antibody - Immunomedics; hA20; Humanised anti-CD20 monoclonal antibody; IMMU-106; Monoclonal antibody hA20; Monoclonal antibody IMMU-106Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Immunomedics
- Developer Immunomedics; Weill Cornell Medical College
- Class Antineoplastics; Antirheumatics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Idiopathic thrombocytopenic purpura; Non-Hodgkin's lymphoma; Rheumatoid arthritis
Most Recent Events
- 02 Dec 2020 Immunomedics terminates a phase I/II trial for Non-Hodgkin's lymphoma (Second-line therapy or greater, Combination therapy) in USA as no subjects were enrolled (NCT01101581)
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 12 Mar 2020 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia in USA (SC)